Ad is loading...
CYTK
Price
$49.10
Change
+$1.43 (+3.00%)
Updated
Nov 22 closing price
88 days until earnings call
DARE
Price
$3.34
Change
+$0.11 (+3.41%)
Updated
Nov 22 closing price
Ad is loading...

CYTK vs DARE

Header iconCYTK vs DARE Comparison
Open Charts CYTK vs DAREBanner chart's image
Cytokinetics
Price$49.10
Change+$1.43 (+3.00%)
Volume$1.64M
CapitalizationN/A
Dare Bioscience
Price$3.34
Change+$0.11 (+3.41%)
Volume$30.18K
CapitalizationN/A
CYTK vs DARE Comparison Chart
Loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
DARE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
CYTK vs. DARE commentary
Nov 25, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a StrongSell and DARE is a Hold.

COMPARISON
Comparison
Nov 25, 2024
Stock price -- (CYTK: $49.10 vs. DARE: $3.34)
Brand notoriety: CYTK and DARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 132% vs. DARE: 66%
Market capitalization -- CYTK: $5.79B vs. DARE: $29.06M
CYTK [@Biotechnology] is valued at $5.79B. DARE’s [@Biotechnology] market capitalization is $29.06M. The market cap for tickers in the [@Biotechnology] industry ranges from $468.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileDARE’s FA Score has 0 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • DARE’s FA Score: 0 green, 5 red.
According to our system of comparison, CYTK is a better buy in the long-term than DARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 2 TA indicator(s) are bullish while DARE’s TA Score has 5 bullish TA indicator(s).

  • CYTK’s TA Score: 2 bullish, 8 bearish.
  • DARE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, DARE is a better buy in the short-term than CYTK.

Price Growth

CYTK (@Biotechnology) experienced а -2.23% price change this week, while DARE (@Biotechnology) price change was +4.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.38%. For the same industry, the average monthly price growth was -4.87%, and the average quarterly price growth was +4.35%.

Reported Earning Dates

CYTK is expected to report earnings on Feb 20, 2025.

DARE is expected to report earnings on Aug 08, 2024.

Industries' Descriptions

@Biotechnology (+2.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($5.79B) has a higher market cap than DARE($29.1M). DARE YTD gains are higher at: -9.924 vs. CYTK (-41.191). DARE has higher annual earnings (EBITDA): -23.19M vs. CYTK (-481.94M). CYTK has more cash in the bank: 1.01B vs. DARE (11.2M). DARE has less debt than CYTK: DARE (1.4M) vs CYTK (790M). CYTK has higher revenues than DARE: CYTK (3.22M) vs DARE (1.88M).
CYTKDARECYTK / DARE
Capitalization5.79B29.1M19,911%
EBITDA-481.94M-23.19M2,078%
Gain YTD-41.191-9.924415%
P/E RatioN/A0.10-
Revenue3.22M1.88M171%
Total Cash1.01B11.2M9,036%
Total Debt790M1.4M56,268%
FUNDAMENTALS RATINGS
CYTK vs DARE: Fundamental Ratings
CYTK
DARE
OUTLOOK RATING
1..100
8371
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
69
Overvalued
PROFIT vs RISK RATING
1..100
49100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5679
P/E GROWTH RATING
1..100
186
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DARE's Valuation (69) in the Biotechnology industry is in the same range as CYTK (100). This means that DARE’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (49) in the Biotechnology industry is somewhat better than the same rating for DARE (100). This means that CYTK’s stock grew somewhat faster than DARE’s over the last 12 months.

CYTK's SMR Rating (100) in the Biotechnology industry is in the same range as DARE (100). This means that CYTK’s stock grew similarly to DARE’s over the last 12 months.

CYTK's Price Growth Rating (56) in the Biotechnology industry is in the same range as DARE (79). This means that CYTK’s stock grew similarly to DARE’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for DARE (86). This means that CYTK’s stock grew significantly faster than DARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKDARE
RSI
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
75%
Momentum
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 3 days ago
77%
MACD
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
77%
Bullish Trend 3 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
74%
Bearish Trend 3 days ago
79%
Advances
ODDS (%)
Bullish Trend 14 days ago
82%
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
76%
Bearish Trend 6 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
78%
Bullish Trend 3 days ago
89%
Aroon
ODDS (%)
Bearish Trend 3 days ago
76%
Bullish Trend 3 days ago
80%
View a ticker or compare two or three
Ad is loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
DARE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
NXTE33.030.57
+1.76%
AXS Green Alpha ETF
PSWD34.040.33
+0.97%
Xtrackers Cybersecurity Select Eq ETF
HKND33.300.23
+0.70%
Humankind US Stock ETF
IFRA51.220.35
+0.69%
iShares US Infrastructure ETF
RLY28.750.02
+0.07%
SPDR® SSgA Multi-Asset Real Return ETF

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with KRON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then KRON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
+3.00%
KRON - CYTK
43%
Loosely correlated
+3.28%
IOVA - CYTK
42%
Loosely correlated
+3.76%
DARE - CYTK
42%
Loosely correlated
+3.41%
CKPT - CYTK
41%
Loosely correlated
+8.07%
DSGN - CYTK
40%
Loosely correlated
+0.90%
More

DARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, DARE has been closely correlated with AZTR. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if DARE jumps, then AZTR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DARE
1D Price
Change %
DARE100%
+3.41%
AZTR - DARE
73%
Closely correlated
+0.43%
CYTK - DARE
42%
Loosely correlated
+3.00%
AXON - DARE
39%
Loosely correlated
+0.90%
AMRN - DARE
34%
Loosely correlated
+4.52%
SNTI - DARE
32%
Poorly correlated
+2.39%
More